Abstract

Objectives This study assessed the prognostic value of peak cardiac power output, measured non-invasively during maximal cardiopulmonary exercise testing, against other exercise-derived haemodynamic variables in patients with chronic congestive heart failure.

Method and Results Two hundred and nineteen unselected, consecutive patients with congestive heart failure (166 men, mean (±SD) age of 56±13 years) who underwent maximal symptom limited cardiopulmonary treadmill exercise testing with non-invasive estimation of cardiac output using carbon dioxide re-breathing techniques, were followed-up for a mean period of 4·64 (4·47–4·82, 95% CI) years. Cardiac power output was calculated from the product of cardiac output and mean arterial blood pressure. All cause mortality was 12·3% (27 deaths). Peak and resting cardiac power output, peak mean arterial blood pressure, peak and resting cardiac output and peak VO2were all predictive of outcome on univariate analyses. Peak cardiac power output, either entered continuously or categorically with a cut-off value of 1·96 watts, was the only independent predictor of mortality (P=0·0004 for values <>1·96 watts and P=0·001 for continuous values) using multivariate analysis. A relative risk ratio of 5·08 (1·94–13·3, 95% CI) was obtained for a cardiac power output <1·96 watts.

Conclusion Peak cardiac power output is an independent predictor of mortality that can be measured non-invasively using cardiopulmonary exercise testing. It can give further prognostic power to a peak VO2in the assessment of patients with congestive heart failure.

f1

Correspondence: Dr Lip-Bun Tan, Consultant Cardiologist, Institute for Cardiovascular Research, Yorkshire Heart Centre, Leeds General Infirmary, Leeds LS1 3EX, U.K.

References

1

Am J Cardiol
.
1999
;
83
:
2
–38A

2

Mancini
DM
, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure.
Circulation
.
1991
;
83
:
778
–786

3

Parameshwar
J
, Keegan J, Sparrow J, Sutton GC, Poole-Wilson PA. Predictors of prognosis in severe chronic heart failure.
Am Heart J
.
1992
;
123
:
421
–426

4

Cohn
JN
, Johnson GR, Shabetai R. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA cooperative studies group.
Circulation
.
1993
;
87
:
VI5
–16

5

Myers
J
, Gullestad L. The role of exercise testing and gas-exchange measurement in the prognostic assessment of patients with heart failure.
Curr Opin Cardiol
.
1998
;
13
:
145
–155

6

Fleg
JL
, Lakata EG. Role of muscle loss in age-associated reduction in VO2 max.
J Appl Physiol
.
1988
;
65
:
1147
–1151

7

Wilson
JR
, Rayos G, Yeoh TK, Gothard P. Dissociation between peak exercise oxygen consumption and haemodynamic dysfunction in potential heart transplant candidates.
J Am Coll Cardiol
.
1995
;
26
:
429
–435

8

Kelly
TL
, Cremo R, Nielsen C, Shabetai R. Prediction of outcome in late-stage cardiomyopathy.
Am Heart J
.
1990
;
119
:
1111
–1121

9

Ghali
JK
, Kadakia S, Bhatt A, Cooper R, Liao Y. Survival of heart failure patients with preserved versus impaired systolic function: the prognostic implication of blood pressure.
Am Heart J
.
1992
;
123
:
993
–997

10

De Groote
P
, Millaire A, Decolouix E, Nugue O, Guimier P, Ducloux G. Kinetics of oxygen consumption during and after exercise in patients with dilated cardiomyopathy.
J Am Coll Cardiol
.
1996
;
28
:
168
–175

11

Osada
N
, Chaitman BR, Miller LW. Cardiopulmonary exercise testing indentifies low risk patients with heart failure and severely impaired exercise considered for heart transplantation.
J Am Coll Cardiol
.
1998
;
31
:
577
–582

12

Pousset
F
, Masson F, Chavirovskaia O. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure.
Eur Heart J
.
2000
;
21
:
1009
–1014

13

Robbins
M
, Francis G, Pashkow F. Ventilatory and heart rate responses to exercise. Better predictors of mortality than peak oxygen consumption.
Circulation
.
1999
;
100
:
2411
–2417

14

Florea
VG
, Henein MY, Anker SD. Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure.
Eur Heart J
.
2000
;
21
:
146
–153

15

Cohen-Solal
A
, Laperche T, Morvan D, Geneves M, Caviezel B, Gourgon R. Prolonged kinetics of recovery of oxygen consumption after maximal graded exercise in patients with chronic heart failure. Analysis with gas exchange measurements and NMR spectroscopy.
Circulation
.
1995
;
91
:
2924
–2932

16

Griffin
BP
, Shah PK, Ferguson J, Rubin SA. Incremental prognostic value of exercise haemodynamic variables in chronic congestive heart failure secondary to coronary artery disease or dilated cardiomyopathy.
Am J Cardiol
.
1991
;
67
:
848
–853

17

Metra
M
, Faggiano P, D'Aloia A. Use of cardiopulmonary exercise testing with haemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure.
J Am Coll Cardiol
.
1999
;
33
:
943
–950

18

Chomsky
DB
, Lang CC, Rayos GH. Haemodynamic exercise testing: A valuable tool in the selection of transplantation candidates.
Circulation
.
1996
;
94
:
3176
–3183

19

Roul
G
, Moulichon ME, Bareiss P. Prognostic factors of chronic heart failure in NYHA class II or II: value of invasive exercise haemodynamic data.
Eur Heart J
.
1995
;
16
:
1387
–1398

20

Cooke
GA
, Marshall P, Al-Timman JK, Wright DJ, Riley R, Tan LB. Physiological cardiac reserve; development of a non-invasive method and first estimates in man.
Heart
.
1998
;
79
:
289
–294

21

Beaver
WL
, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange.
J Appl Physiol
.
1986
;
60
:
2020
–2027

22

Collier
CR
. Determination of mixed venous CO2 by re-breathing.
J Appl Physiol
.
1956
;
9
:
25
–29

23

Defares
JG
. Determination of pvCO2 from the exponential CO2 rise during rebreathing.
J Appl Physiol
.
1958
;
13
:
159
–164

24

Becklake
MR
, Frank H, Dagenais GR, Ostiguy GL, Guzman CA. Influence of age and sex on exercise cardiac output.
J Appl Physiol
.
1965
;
20
:
938
–947

25

Wasserman
K
, Hansen JE, Sue DY, Whipp BJ, Casburi R. Principles of Exercise Testing and Interpretation. : Lea and Febiger; 1994.

26

Cohen-Solal
A
, Barnier P, Pessione F. Comparison of the long term prognostic value of peak exercise oxygen pulse and peak oxygen uptake in patients with chronic heart failure.
Heart
.
1997
;
78
:
572
–576

27

Slazchic
J
, Massie B, Kramer B. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure.
Am J Cardiol
.
1985
;
55
:
1037
–1042

28

Stevenson
LW
, Couper G, Natterson B. Target heart failure populations for newer therapies.
Circulation
.
1995
;
92
:
II174
–81

29

Weber
KT
, Kinasewitz GT, Janicki JS. Oxygen utilisation and ventilation during exercise in patients with chronic cardiac failure.
Circulation
.
1982
;
65
:
1213
–1223

30

Meiler
SEL
, Ashton JJ, Moeschberger MC. An analysis of the determinants of exercise performance in congestive heart failure.
Am Heart J
.
1987
;
113
:
1207
–1217

31

Tan
LB
. Cardiac pumping capability and prognosis in heart failure.
Lancet
.
1986
;
ii
:
1360
–1363

32

Tan
LB
. Clinical and research implications of new concepts in the assessment of cardiac pumping performance in heart failure.
Cardiovasc Res
.
1987
;
21
:
615
–622

33

Yu
CM
, Sanderson JE, Shum. Diastolic dysfunction and natriuretic peptides in systolic heart failure: higher ANP and BNP levels are associated with a restrictive filling pattern.
Eur Heart J
.
1996
;
17
:
1694
–1702

34

Selvais
PL
, Donckier JE, Robert A. Cardiac natriuretic peptides for risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation.
Eur J Clin Invest
.
1998
;
28
:
636
–642

35

Richards
AM
, Nicholls MG, Yandle TG. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction.
Circulation
.
1998
;
97
:
1921
–1929

36

Tsutamoto
T
, Wada A, Maeda K. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction: comparison with plasma angiotensin II and endothelin-1.
Eur Heart J
.
1998
;
20
:
1799
–1807

37

Leyva
F
, Anker S, Swan JW. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure.
Eur Heart J
.
1997
;
18
:
858
–865

38

Leyva
F
, Anker SD, Godsland IF. Uric acid in chronic heart failure: a marker of chronic inflammation.
Eur Heart J
.
1998
;
19
:
1814
–1822

39

Cohn
JN
, Levine TB, Olivari MT. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.
N Engl J Med
.
1984
;
311
:
819
–823

40

Francis
GS
, Cohn JN, Johnson G. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative studies group.
Circulation
.
1993
;
87
:
V40
–48

41

Bain
RJI
, Tan LB, Murray RG, Davies MK, Littler WA. The correlation of cardiac power output to exercise capacity in chronic heart failure.
Eur J Appl Physiol
.
1990
;
61
:
112
–118

42

Tan
LB
. Evaluation of cardiac dysfuncton, cardiac reserve and inotropic response.
Postgrad Med J
.
1991
;
67
:
S10
–20

This content is only available as a PDF.